candesartan has been researched along with Coronary Restenosis in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wakeyama, T | 1 |
| Ogawa, H | 1 |
| Iida, H | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Mochizuki, M | 1 |
| Tanaka, T | 1 |
| Krämer, J | 1 |
| Ruf, RG | 1 |
| Schmidt, S | 1 |
| Axthelm, C | 1 |
| Strasser, R | 1 |
| Janssen, G | 1 |
| Thieme, T | 1 |
| Kusch, A | 1 |
| Waigand, J | 1 |
| Dietz, R | 1 |
| Gross, CM | 1 |
2 trials available for candesartan and Coronary Restenosis
| Article | Year |
|---|---|
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Co | 2003 |
The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial--a multicenter study of AT1-receptor blocker therapy in coronary stenting.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Vessel Prosthesis | 2008 |